Esperion Aims Low On Price For Cholesterol Drug Bempedoic Acid

Esperion is emphasizing the low list and net price of its oral bempedoic acid for cholesterol reduction, relative to the injectable PCSCK9 inhibitors, but still significantly higher than other oral cholesterol-lowering drugs.

US-Money-and-Pills_V2_1200x675

Esperion Therapeutics Inc. has a tough hill to climb if it gets to market with its cholesterol therapy bempedoic acid, a feat that has proven challenging for the highly effective PCSK9 inhibitors. The company is betting that if the drug costs payers and patients less than the injectable PCSK9 inhibitors that will help it gain traction.

Esperion is aiming for an annual list price of $3,500 and now is guiding for a net price of about...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip